# Antimicrobial Agents and Asthma Morbidity among African American Children with Asthma > **NIH NIH K01** · JOHNS HOPKINS UNIVERSITY · 2020 · $133,286 ## Abstract PROJECT SUMMARY/ABSTRACT Asthma is the leading chronic pediatric disease in the U.S., disproportionately affecting African American children. Because asthma has no cure, identifying triggers is critical for disease management and control. Emerging evidence, including our preliminary data, suggests that some of the most commonly used antimicrobial agents in personal care products (PCPs), parabens and triclosan, may be asthma triggers and contribute to increased asthma morbidity. Still, studies relating exposure to antimicrobial agents in PCPs with asthma morbidity are scarce and no studies have assessed this risk among highly vulnerable populations experiencing both high morbidity and high exposure to antimicrobial agents. These potential associations are particularly relevant to African American (AA) children as they have biomarker concentrations for select antimicrobial agents that are nearly 8 times higher than White children, they are twice as likely to have asthma, and are 10 times more likely to die of asthma complications than their non-AA peers. By leveraging infrastructure and two Johns Hopkins pediatric cohort studies the proposed research will be the first to: (1) examine the effects of parabens and triclosan on asthma morbidity among AA children with asthma using longitudinal data; (2) apply qualitative research methods to develop a culturally-tailored PCP survey to identify use patterns associated with exposures to these compounds; and (3) conduct a pilot intervention with antimicrobial-free PCPs to inform future intervention research. Results from this work have the potential to lead to effective public health strategies to improve asthma-related outcomes for children with asthma. This project is also in line with NHLBI’s research agenda to solve problems related to pulmonary diseases in populations suffering disproportionately from these conditions. Dr. Quiros-Alcala is an environmental health scientist by training, and this career development award will provide her with an exceptional training platform to acquire new complementary skills crucial to achieve independence, including in pediatric respiratory disease, qualitative research methods, structural equation modeling, and intervention design and implementation. Expertise in these areas will be acquired under the guidance of an interdisciplinary mentoring team of content area experts from the candidate’s home institution, the University of Maryland, and the Johns Hopkins School of Medicine and Bloomberg School of Public Health. The career development plan entails a structured approach to mentoring, didactic coursework, field and clinic experience, participation in scientific meetings, and regular assessment of career milestones. The strong mentoring team and institutional environments will ensure the successful completion of all training and research activities during the award period. In summary, this award will provide the candidate with protected time to acquire the necessary... ## Key facts - **NIH application ID:** 9988481 - **Project number:** 5K01HL138124-04 - **Recipient organization:** JOHNS HOPKINS UNIVERSITY - **Principal Investigator:** Lesliam Quiros-Alcala - **Activity code:** K01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2020 - **Award amount:** $133,286 - **Award type:** 5 - **Project period:** 2017-08-01 → 2022-07-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/9988481 ## Citation > US National Institutes of Health, RePORTER application 9988481, Antimicrobial Agents and Asthma Morbidity among African American Children with Asthma (5K01HL138124-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9988481. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*